Should You Buy Amgen Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Amgen Inc. (AMGN) is rated as a strong fundamental performer with a QOC score of 8.4/10. Trading at $375.65, our valuation engine evaluates whether the market price reflects the company's underlying earnings power.
The short answer: 3 of 10 CirclFi valuation models project upside for Amgen Inc. (AMGN) at $375.65 — the model consensus leans bearish, with a Quality Score of 8.4/10 and Value-Trap risk of 12/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Amgen Inc. (AMGN) in 2026?
What Is the Bull Case vs the Bear Case for Amgen Inc. (AMGN)?
| Bull case — $684.93 target (+82.3%) | Bear case — $173.54 target (-53.8%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Amgen Inc.'s rating of 8.4/10 signals strong fundamentals — high-quality businesses tend to compound value more reliably. | According to the CirclFi Deep Alpha Valuation Engine, the EROIC Spread model sees the stock as overvalued with a fair value of $173.54 (-53.8%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $684.93 (+82.3%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +136.1% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| Industry tailwind: licensing and M&A optionality could provide meaningful support for Amgen Inc.'s revenue and margin trajectory in the Drug Manufacturers - General space. | Industry headwind: generic/biosimilar competition represents a meaningful risk for Amgen Inc. and its Drug Manufacturers - General peers. |
| The company's $203.1B market capitalization provides liquidity, stability, and the resource base to invest through downturns — structural advantages over smaller peers. |
How Does AMGN Compare to Its Drug Manufacturers - General Peers?
Valuation data pages: BMY · BIIB · GSK · ABBV · JNJ · SNY · OGN · MDCX · LLY · GILD · MRK
Which Other Stocks Score Like AMGN on Quality?
Closest companies to AMGN’s Quality of Company score of 8.4/10, across all industries.
- GAP — The Gap, Inc. (QOC 8.4) · analysis
- AWX — Avalon Holdings Corporation (QOC 8.4) · analysis
- FUNC — First United Corporation (QOC 8.4) · analysis
- CXM — Sprinklr, Inc. (QOC 8.4) · analysis
- MLM — Martin Marietta Materials, Inc. (QOC 8.4) · analysis
- XTNT — Xtant Medical Holdings, Inc. (QOC 8.4) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
So Is Amgen Inc. (AMGN) Worth Buying in 2026?
Caution dominates our read on Amgen Inc. at $375.65. 7 of 10 models see limited upside or outright downside, with the median fair value at $296.64 (-21.0%). Quality at 8.4/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.
These are quantitative model outputs, not investment recommendations. Amgen Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About AMGN Stock?
Should I buy AMGN stock right now?
Based on CirclFi's multi-model analysis, 3 of 10 models see upside for AMGN at $375.65. The models are divided, which means the investment case depends heavily on your assumptions about Amgen Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Amgen Inc.?
Key risks include: wide model disagreement (295% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - General companies. Always diversify and consult a financial advisor.
How does AMGN compare to its competitors?
Among Drug Manufacturers - General peers, AMGN holds a Quality Score of 8.4/10. Comparable companies include BMY (QOC 8.5), BIIB (QOC 7.9), GSK (QOC 8.5). The relative ranking helps investors identify whether AMGN offers better fundamental quality than alternatives in the same sector.
Is AMGN a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. AMGN's Quality Score of 8.4/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy AMGN at?
CirclFi does not provide target buy prices or price alerts. However, our 10 active models produce fair value estimates ranging from $173.54 to $684.93. At $375.65, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for AMGN.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad